Clinical Trials Logo

DLBCL clinical trials

View clinical trials related to DLBCL.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05498636 Not yet recruiting - DLBCL Clinical Trials

SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

Start date: October 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a phase II multi-center prospective clinical trail which investigates the efficacy and safety of Selinexor combined with prednisone, etoposide and lenalidomide in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patient with high p53 and/or c-myc expression.

NCT ID: NCT05381506 Not yet recruiting - DLBCL Clinical Trials

Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma

O-Gemox
Start date: July 2022
Phase: Phase 2
Study type: Interventional

This study aims to investigate the treatment of refractory or relapsed DLBCL with orelabrutinib and gemox. The primary endpoint is response rate (complete response rate and overall response rate), and the second endpoints are survival time (OS and PFS) and toxicities.

NCT ID: NCT05093140 Not yet recruiting - DLBCL Clinical Trials

Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL

CREDIT
Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

To assess the efficacy and safety of camrelizumab combined with rituximab, vincristine, doxorubicin, cyclophosphamide and prednisone in the treatment of untreated primary extranodal DLBCL

NCT ID: NCT05039658 Not yet recruiting - DLBCL Clinical Trials

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

Start date: September 27, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether treatment with IBI110 single agent and in combination with sintilimab demonstrates sufficient efficacy/safety in r/r DLBCL.

NCT ID: NCT04994626 Not yet recruiting - Relapse Clinical Trials

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Ibrutinib Combined With Rituximab in Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies.

NCT ID: NCT04842487 Not yet recruiting - DLBCL Clinical Trials

R2-CHOP in Untreated DEL-DLBCL:An Open-lable,Multicenter,Phase II Study

Start date: April 10, 2021
Phase: Phase 2
Study type: Interventional

To assess the efficacy and safety of lenalidomide combined with rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisone (r2-chop) in the initial treatment of DEL-DLBCL. The primary endpoint is the complete response rate, and the second endpoints are survival time (OS and PFS) and overall response rate.

NCT ID: NCT03123718 Not yet recruiting - DLBCL Clinical Trials

High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL

Start date: July 1, 2017
Phase: Phase 3
Study type: Interventional

The outcome of patients with central nervous system (CNS) relapse in DLBCL is poor, with median survival times of 2-5 months. This fatal prognosis necessitates CNS prevention in a subgroup of patients with a high risk of CNS relapse. Intrathecal methotrexate (ITMTX) has traditionally been used, although its efficacy for CNS prophylaxis is contradictory. High-dose intravenous methotrexate (IVMTX) has been suggested as an alternative approach. Considering the lack of evidence supporting the role of ITMTX, the investigators propose to compare the efficacy of ITMTX and IVMTX for prophylaxis of CNS relapse in a subgroup of patients with DLBCL at a high risk for CNS relapse.